Related references
Note: Only part of the references are listed.Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor
Yuanying Fang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist
Lijun Hu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Primary biliary cholangitis: pathogenesis and therapeutic opportunities
Aliya F. Gulamhusein et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Current and potential treatments for primary biliary cholangitis
Raj A. Shah et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury
Valentina Sepe et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Farnesoid X receptor modulators 2014-present: a patent review
Valentina Sepe et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2018)
The Ascending Pathophysiology of Cholestatic Liver Disease
Peter L. M. Jansen et al.
HEPATOLOGY (2017)
Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice
Yang Xu et al.
HEPATOLOGY (2016)
Role of farnesoid X receptor in cholestasis
Zhi Qing Yuan et al.
JOURNAL OF DIGESTIVE DISEASES (2016)
Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases
Yanping Xu
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Prospective Evaluation of Ursodeoxycholic Acid Withdrawal in Patients With Primary Sclerosing Cholangitis
Ewa Wunsch et al.
HEPATOLOGY (2014)
Extending the Structure-Activity Relationship of Anthranilic Acid Derivatives As Farnesoid X Receptor Modulators: Development of a Highly Potent Partial Farnesoid X Receptor Agonist
Daniel Merk et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The metabolomic window into hepatobiliary disease
Diren Beyoglu et al.
JOURNAL OF HEPATOLOGY (2013)
Conformationally constrained farnesoid X receptor (FXR) agonists: Alternative replacements of the stilbene
Adwoa Akwabi-Ameyaw et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR)
Brenton Flatt et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064
Adwoa Akwabi-Ameyaw et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: Implications for interindividual variability in response to drugs
Bradley L. Urquhart et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Share Paper
